Consulting Agreements in the Biotechnology Industry

1,037 Contracts & Agreements

Browse by Company

2seventy bio, Inc. (1 contract)
Accustem Sciences Inc. (3)
Achaogen, Inc. (1)
Acorda Therapeutics (3)
Actinium Pharmaceuticals, Inc. (3)
Adagio Therapeutics, Inc. (2)
Adamas Pharmaceuticals Inc (7)
Adaptimmune Therapeutics PLC (1)
Adhera Therapeutics, Inc. (2)
ADiTx Therapeutics, Inc. (4)
ADMA BIOLOGICS, INC. (1)
ADURO BIOTECH, INC. (3)
Advaxis, Inc. (1)
Adverum Biotechnologies, Inc. (10)
Aeglea BioTherapeutics, Inc. (6)
AGENUS INC (11)
AgeX Therapeutics, Inc. (1)
AGIOS PHARMACEUTICALS INC (2)
AILERON THERAPEUTICS INC (2)
AKCEA THERAPEUTICS, INC. (4)
Akebia Therapeutics, Inc. (2)
Akouos, Inc. (1)
ALBIREO PHARMA, INC. (2)
Aldeyra Therapeutics, Inc. (2)
Alector, Inc. (1)
Alexion Pharmaceuticals (2)
Aligos Therapeutics, Inc. (2)
Alliqua BioMedical, Inc. (7)
Allogene Therapeutics, Inc. (3)
Allovir, Inc. (4)
ALNYLAM PHARMACEUTICALS, INC. (2)
Altimmune, Inc. (3)
Alzamend Neuro, Inc. (1)
AMARILLO BIOSCIENCES INC (3)
AMARIN CORP PLC (1)
Amgen Inc. (3)
AMICUS THERAPEUTICS, INC. (2)
AmpliPhi Biosciences Corp (1)
ANAPTYSBIO INC (2)
ANAVEX LIFE SCIENCES CORP. (9)
Anchiano Therapeutics Ltd. (1)
Anika Therapeutics (3)
Apellis Pharmaceuticals, Inc. (2)
Applied Molecular Transport Inc. (1)
Aptose Biosciences Inc. (1)
AquaBounty Technologies, Inc. (1)
AQUINOX PHARMACEUTICALS, INC (6)
Aravive, Inc. (3)
Arbutus Biopharma Corp (3)
ARCA biopharma, Inc. (1)
Arcellx, Inc. (1)
Arcus Biosciences, Inc. (4)
Arcutis Biotherapeutics, Inc. (1)
ARENA PHARMACEUTICALS INC (2)
Arsanis, Inc. (1)
Artiva Biotherapeutics, Inc. (1)
ASSEMBLY BIOSCIENCES, INC. (3)
Athenex, Inc. (2)
ATHERSYS, INC (1)
Atreca, Inc. (4)
Aura Biosciences, Inc. (1)
AVEO PHARMACEUTICALS INC (3)
Avidity Biosciences, Inc. (1)
AVROBIO, Inc. (2)
BeiGene, Ltd. (5)
BELLICUM PHARMACEUTICALS, INC (8)
BICYCLE THERAPEUTICS Ltd (1)
bioAffinity Technologies, Inc. (1)
BioCardia, Inc. (2)
Biogen Inc. (3)
Biohaven Pharmaceutical Holding Co Ltd. (1)
BIOMARIN PHARMACEUTICAL INC (2)
BioNexus Gene Lab Coporation (1)
BioRestorative Therapies, Inc. (1)
BIOSPECIFICS TECHNOLOGIES CORP (3)
Biostage, Inc. (1)
BIOTIME INC (7)
BIOXYTRAN, INC (1)
Blue Water Vaccines Inc. (2)
bluebird bio, Inc. (2)
Blueprint Medicines Corp (1)
Bolt Biotherapeutics, Inc. (1)
Bone Biologics Corp (3)
BRAINSTORM CELL THERAPEUTICS INC. (1)
BridgeBio Pharma, Inc. (1)
BullFrog AI Holdings, Inc. (1)
BURZYNSKI RESEARCH INSTITUTE INC (1)
C4 Therapeutics, Inc. (1)
Cabaletta Bio, Inc. (2)
CALADRIUS BIOSCIENCES, INC. (2)
Calyxt, Inc. (2)
CANCER GENETICS, INC (7)
Candel Therapeutics, Inc. (3)
CAPRICOR THERAPEUTICS, INC. (2)
Capstone Therapeutics Corp. (1)
CareDx, Inc. (3)
CASTLE BIOSCIENCES INC (1)
Castle Creek Biosciences, Inc. (3)
CATABASIS PHARMACEUTICALS INC (2)
CATALYST BIOSCIENCES, INC. (3)
CATALYST PHARMACEUTICALS, INC. (4)
Cellectar Biosciences, Inc. (1)
Cellular Biomedicine Group, Inc. (1)
Celsion CORP (1)
CEREBAIN BIOTECH CORP. (2)
Chardan Healthcare Acquisition 2 Corp. (2)
CHIMERIX INC (3)
Cidara Therapeutics, Inc. (2)
CLEVELAND BIOLABS INC (5)
CohBar, Inc. (3)
Conatus Pharmaceuticals Inc. (2)
CONSTELLATION PHARMACEUTICALS INC (3)
CONTRAFECT Corp (3)
Corbus Pharmaceuticals Holdings, Inc. (1)
Corvus Pharmaceuticals, Inc. (1)
Crinetics Pharmaceuticals, Inc. (1)
CRISPR Therapeutics AG (1)
CTI BIOPHARMA CORP (1)
Cue Biopharma, Inc. (3)
Cullinan Oncology, LLC (5)
Curative Biotechnology Inc (3)
CURIS INC (13)
Cyclacel Pharmaceuticals, Inc. (1)
Cyclerion Therapeutics, Inc. (1)
CytoDyn Inc. (8)
Cytokinetics, Incorporated (4)
CytomX Therapeutics, Inc. (7)
CYTORI THERAPEUTICS, INC. (3)
Decibel Therapeutics, Inc. (2)
Deciphera Pharmaceuticals, Inc. (1)
DelMar Pharmaceuticals, Inc. (8)
Design Therapeutics, Inc. (5)
DiaMedica Therapeutics Inc. (2)
Diffusion Pharmaceuticals Inc. (3)
Digital Development Partners, Inc. (1)
Dynamics Special Purpose Corp. (1)
DYNAVAX TECHNOLOGIES CORP (3)
Dyne Therapeutics, Inc. (1)
Eagle Pharmaceuticals, Inc. (1)
Edge Therapeutics, Inc. (4)
Editas Medicine, Inc. (1)
Eiger BioPharmaceuticals, Inc. (1)
Eliem Therapeutics, Inc. (3)
Emergent BioSolutions Inc. (6)
Enanta Pharmaceuticals, Inc. (2)
Enochian Biosciences Inc (7)
Entera Bio Ltd. (2)
ENZOLYTICS INC (1)
Epizyme, Inc. (8)
Evelo Biosciences, Inc. (3)
EXACT SCIENCES CORP (1)
Exelixis (2)
EXICURE, INC. (1)
FATE THERAPEUTICS INC (1)
FIBROGEN INC (3)
Finch Therapeutics Group, Inc. (1)
FIVE PRIME THERAPEUTICS INC (4)
Flex Pharma, Inc. (2)
Flexion Therapeutics Inc (1)
FLUOROPHARMA MEDICAL, INC. (1)
Foghorn Therapeutics Inc. (4)
Fortress Biotech, Inc. (1)
FS Development Corp. II (2)
G1 Therapeutics, Inc. (1)
Gain Therapeutics, Inc. (2)
GALECTIN THERAPEUTICS INC (6)
Gamida Cell Ltd. (3)
Gemphire Therapeutics Inc. (3)
Generation Bio Co. (2)
GENOCEA BIOSCIENCES, INC. (3)
Genprex, Inc. (1)
GeoVax Labs, Inc. (4)
GERON CORP (1)
GLYCOMIMETICS INC (2)
Grail, Inc. (1)
Greater Cannabis Company, Inc. (2)
GTX INC (3)
GX Acquisition Corp. (1)
Harpoon Therapeutics, Inc. (3)
Health Sciences Acquisitions Corp (1)
HedgePath Pharmaceuticals, Inc. (1)
HEMISPHERX BIOPHARMA INC (2)
HISTOGENICS CORP (2)
Homology Medicines, Inc. (3)
HUMANIGEN, INC (2)
iBio, Inc. (2)
IDEAYA Biosciences, Inc. (1)
IDERA PHARMACEUTICALS, INC. (10)
Imago BioSciences, Inc. (1)
Immune Therapeutics, Inc. (8)
ImmunoCellular Therapeutics, Ltd. (2)
Immunome Inc. (2)
IMMUNOMEDICS INC (1)
INFINITY PHARMACEUTICALS, INC. (3)
Inhibikase Therapeutics, Inc. (2)
InMed Pharmaceuticals Inc. (2)
Inmune Bio, Inc. (1)
INOVIO PHARMACEUTICALS, INC. (1)
Inozyme Pharma, Inc. (3)
INSMED Inc (1)
INTERCEPT PHARMACEUTICALS, INC. (8)
International Stem Cell CORP (4)
Invitae Corp (1)
IOVANCE BIOTHERAPEUTICS, INC. (5)
IRONWOOD PHARMACEUTICALS INC (3)
Isoray, Inc. (2)
iTeos Therapeutics, Inc. (2)
Janux Therapeutics, Inc. (1)
Karyopharm Therapeutics Inc. (10)
KBL MERGER CORP. IV (7)
Kezar Life Sciences, Inc. (1)
Kiromic Biopharma, Inc. (5)
KIWA BIO-TECH PRODUCTS GROUP CORP (1)
Kronos Bio, Inc. (1)
Leisure Acquisition Corp. (1)
LEXICON PHARMACEUTICALS, INC. (1)
LianBio (1)
LifeSci Acquisition Corp. (1)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (1)
Locust Walk Acquisition Corp. (1)
LogicBio Therapeutics, Inc. (2)
LONGEVERON LLC (1)
MACROGENICS INC (1)
MANHATTAN SCIENTIFICS INC (1)
MARIZYME INC (4)
Marker Therapeutics, Inc. (5)
MATEON THERAPEUTICS INC (6)
Matinas BioPharma Holdings, Inc. (2)
MAXCYTE, INC. (1)
MEDICINOVA INC (4)
Medovex Corp. (2)
MeiraGTx Holdings plc (1)
MERRIMACK PHARMACEUTICALS INC (1)
Merus N.V. (1)
Metacrine, Inc. (4)
Millendo Therapeutics, Inc. (3)
MiMedx Group, Inc. (4)
Minerva Neurosciences, Inc. (5)
MIRAGEN THERAPEUTICS, INC. (4)
Mirati Therapeutics, Inc. (3)
Mirum Pharmaceuticals, Inc. (1)
Moderna, Inc. (3)
Moleculin Biotech, Inc. (1)
Momenta Pharmaceuticals, Inc. (5)
Monopar Therapeutics (11)
Morphic Holding, Inc. (3)
MYMETICS CORP (1)
Myovant Sciences Ltd. (2)
Myriad Genetics, Inc. (4)
NAVIDEA BIOPHARMACEUTICALS, INC. (3)
NEUROBIOLOGICAL TECHNOLOGIES INC (1)
Neurotrope, Inc. (6)
NextCure, Inc. (1)
NOVAVAX INC (7)
Novus Therapeutics, Inc. (3)
NTN BUZZTIME INC (8)
Nuo Therapeutics, Inc. (2)
Ohr Pharmaceutical Inc (2)
Olema Pharmaceuticals, Inc. (1)
Olivia Ventures, Inc. (1)
Omega Therapeutics, Inc. (4)
OncBioMune Pharmaceuticals, Inc (5)
OncoCyte Corp (2)
OPGEN INC (3)
Ophthotech Corp. (2)
Organicell Regenerative Medicine, Inc. (4)
ORGANOVO HOLDINGS, INC. (6)
Orgenesis Inc. (6)
Outlook Therapeutics, Inc. (5)
Ovid Therapeutics Inc. (1)
Pasithea Therapeutics Corp. (2)
Passage BIO, Inc. (2)
PDL BIOPHARMA, INC. (1)
PharmaCyte Biotech, Inc. (6)
PIERIS PHARMACEUTICALS, INC. (4)
PLURISTEM THERAPEUTICS INC (6)
PMV Pharmaceuticals, Inc. (5)
POLARITYTE, INC. (2)
PORTOLA PHARMACEUTICALS INC (1)
PRECISION BIOSCIENCES INC (2)
PREDICTIVE TECHNOLOGY GROUP, INC. (1)
Prelude Therapeutics Inc (1)
PREMIER BIOMEDICAL INC (1)
Progenics Pharmaceuticals, Inc. (2)
Protagenic Therapeutics, Inc. (7)
PROTEON THERAPEUTICS INC (3)
PROTEOSTASIS THERAPEUTICS, INC. (4)
Prothena Corp plc (5)
ProtoKinetix, Inc. (15)
PTC THERAPEUTICS, INC. (4)
Q BioMed Inc. (1)
Qrons Inc. (2)
Radius Health, Inc. (7)
RAPT Therapeutics, Inc. (2)
Regulus Therapeutics Inc. (1)
Reneo Pharmaceuticals, Inc. (2)
RenovaCare, Inc. (8)
RenovoRx, Inc. (8)
Replimune Group, Inc. (1)
Retrophin, Inc. (1)
REXAHN PHARMACEUTICALS, INC. (8)
RHYTHM PHARMACEUTICALS, INC. (3)
RIGEL PHARMACEUTICALS INC (1)
RITTER PHARMACEUTICALS INC (7)
ROCKET PHARMACEUTICALS, INC. (1)
Sage Therapeutics, Inc. (1)
Sana Biotechnology, Inc. (1)
Sarepta Therapeutics, Inc. (3)
Savara Inc (4)
Scholar Rock Holding Corp (1)
SEATTLE GENETICS INC (1)
SELECTA BIOSCIENCES INC (5)
SELLAS Life Sciences Group, Inc. (1)
SERA PROGNOSTICS, INC. (2)
Seres Therapeutics, Inc. (1)
Sesen Bio, Inc. (4)
Shuttle Pharmaceuticals Holdings, Inc. (2)
Sierra Oncology, Inc. (1)
Sigilon Therapeutics, Inc. (3)
Silverback Therapeutics, Inc. (6)
SOLENO THERAPEUTICS INC (2)
Solid Biosciences Inc. (11)
SOLIGENIX, INC. (1)
Sorrento Therapeutics, Inc. (3)
Spectrum Pharmaceuticals, Inc. (1)
Spero Therapeutics, Inc. (8)
SPHERIX INC (1)
Spring Bank Pharmaceuticals, Inc. (3)
SpringWorks Therapeutics, Inc. (2)
SPRUCE BIOSCIENCES, INC. (1)
SQZ Biotechnologies Co (2)
Stoke Therapeutics, Inc. (1)
Sun BioPharma, Inc. (2)
SUNESIS PHARMACEUTICALS INC (4)
Syndax Pharmaceuticals Inc (1)
SYNLOGIC, INC. (1)
Synthetic Biologics, Inc. (3)
Syros Pharmaceuticals, Inc. (2)
TENAX THERAPEUTICS, INC. (6)
Therapeutics Acquisition Corp. (2)
Tonix Pharmaceuticals Holding Corp. (3)
Translate Bio, Inc. (3)
Turning Point Therapeutics, Inc. (3)
U.S. Stem Cell, Inc. (2)
uniQure N.V. (2)
Unum Therapeutics Inc. (1)
USA EQUITIES CORP. (2)
Vaxart, Inc. (3)
VBI Vaccines Inc (10)
Vera Therapeutics, Inc. (1)
Verastem, Inc. (6)
Vericel Corp (1)
VICAL INC (12)
Viela Bio, Inc. (1)
VistaGen Therapeutics, Inc. (7)
VITRO DIAGNOSTICS INC (3)
Voyager Therapeutics, Inc. (11)
Xencor Inc (1)
Xenon Pharmaceuticals Inc. (1)
Xilio Therapeutics, Inc. (1)
XOMA Corp (2)
Yulong Eco-Materials Ltd (1)
Zentalis Pharmaceuticals, LLC (2)
ZIOPHARM ONCOLOGY INC (6)

Recent Contracts

Consulting Agreement, dated April 17, 2024, by and between the Company and Veronica Jordan (BICYCLE THERAPEUTICS Ltd, Filed With SEC on April 18, 2024)
Consulting Agreement between Ocuphire Pharma, Inc. and Jay Pepose, M.D., dated April 11, 2024 (REXAHN PHARMACEUTICALS, INC., Filed With SEC on April 17, 2024)
Amendment to Consulting Agreement with F. Diaz-Mitoma Professional Corporation, effective January 1, 2024 (VBI Vaccines Inc, Filed With SEC on April 16, 2024)
Consulting Agreement between the Company and Rapid Deployment LLC (CytoDyn Inc., Filed With SEC on April 15, 2024)
Consulting Agreement, dated April 10, 2024, by and between Prelude Therapeutics Incorporated and Laurent Chardonnet (Prelude Therapeutics Inc, Filed With SEC on April 10, 2024)
Consulting Agreement, by and between ARCA and Michael Bristow, dated as of April 3, 2024 (ARCA biopharma, Inc., Filed With SEC on April 4, 2024)
Consulting Agreement, dated as of February 21, 2024, between the Registrant and Ferdinand Groenewald (ZIOPHARM ONCOLOGY INC, Filed With SEC on April 1, 2024)
Consulting Agreement, dated as of December 22, 2023, between the Registrant and Kevin S. Boyle, Sr (ZIOPHARM ONCOLOGY INC, Filed With SEC on April 1, 2024)
Consulting Agreement, dated as of November 14, 2023, between the Registrant and Melinda Lackey (ZIOPHARM ONCOLOGY INC, Filed With SEC on April 1, 2024)
Amendment to Consulting Agreement by and between Richard A. Young and the Registrant, dated October 6, 2023 (Omega Therapeutics, Inc., Filed With SEC on March 28, 2024)
Amendment to Consulting Agreement by and between Richard A. Young and the Registrant, dated October 5, 2022 (Omega Therapeutics, Inc., Filed With SEC on March 28, 2024)
Consulting by and between Candel Therapeutics, Inc. and Jason A. Amello, dated as of January 12, 2024 (Candel Therapeutics, Inc., Filed With SEC on March 28, 2024)
Separation and Consulting Agreement, dated February 13, 2023, by and between Eliem Therapeutics, Inc. and James B. Bucher (Eliem Therapeutics, Inc., Filed With SEC on March 28, 2024)
CONSULTING AGREEMENT (Monopar Therapeutics, Filed With SEC on March 28, 2024)
Consulting Agreement dated October 2, 2023, by and between the Registrant and Dennis Giesing (Immunome Inc., Filed With SEC on March 28, 2024)
Second Amended and Restated Consulting Agreement, effective December 31, 2023, by and between Terry Coelho and Gamida Cell Ltd (Gamida Cell Ltd., Filed With SEC on March 27, 2024)
Consulting Agreement, dated March 25, 2024, between the Company and Joshua Brumm (Dyne Therapeutics, Inc., Filed With SEC on March 25, 2024)
Consulting Agreement with Mark Smith, dated May 25, 2023 (Finch Therapeutics Group, Inc., Filed With SEC on March 25, 2024)
Consulting Agreement by and between Cyclacel Pharmaceuticals, Inc. and Brian Schwartz, M.D., dated January 26, 2024 (Cyclacel Pharmaceuticals, Inc., Filed With SEC on March 21, 2024)
Consulting Agreement by and between the Registrant and Rodney Lappe, Ph.D., dated November 22, 2023 (Design Therapeutics, Inc., Filed With SEC on March 19, 2024)
Third Amendment to Consulting Agreement, by and between the Registrant and Aseem Z. Ansari, Ph.D., dated November 9, 2023 (Design Therapeutics, Inc., Filed With SEC on March 19, 2024)
Separation and Consulting Agreement and Release, dated as of March 18, 2024, by and between the Company and Jathin Bandari, M.D (PROTEON THERAPEUTICS INC, Filed With SEC on March 18, 2024)
First Amendment to Consulting Agreement, dated December 16, 2023, by and between the Registrant and Alison Moore, Ph.D (Allogene Therapeutics, Inc., Filed With SEC on March 14, 2024)
Amendment to Consulting Agreement between Agenus Inc. and Brian Corvese, dated December 31, 2023 (AGENUS INC, Filed With SEC on March 14, 2024)
Consulting Agreement, dated February 9, 2024, by and between the Registrant and Tamara Joseph (Spero Therapeutics, Inc., Filed With SEC on March 13, 2024)
Consulting Agreement, dated March 11, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC (Enochian Biosciences Inc, Filed With SEC on March 13, 2024)
Consulting agreement, dated June 2, 2019, between Entera Bio Ltd. and Dana Yaacov Garbeli (through A2Z Finance Ltd.), as amended (Entera Bio Ltd., Filed With SEC on March 8, 2024)
Separation, Release and Consulting Agreement dated November 30, 2023 between Registrant and Gary S. Hogge (BIOTIME INC, Filed With SEC on March 7, 2024)
Consulting Agreement between Foghorn Therapeutics Inc. and Ian F. Smith, dated as of December 8, 2023 (Foghorn Therapeutics Inc., Filed With SEC on March 7, 2024)
Consulting Agreement with Peter Hecht dated December 1, 2023 (Cyclerion Therapeutics, Inc., Filed With SEC on March 5, 2024)
Consulting Agreement, dated effective July 7, 2023, by and between Elizabeth A. Howard and Arbutus Biopharma Corporation (Arbutus Biopharma Corp, Filed With SEC on March 5, 2024)
Consulting Agreement by and between the Company and Mark McKenna, effective August 1, 2023 (Aeglea BioTherapeutics, Inc., Filed With SEC on March 1, 2024)
Consulting Agreement, dated February 13, 2024, by and between the Registrant and Charles Baum, MD., Ph.D (PMV Pharmaceuticals, Inc., Filed With SEC on February 29, 2024)
Consulting Agreement, dated January 5, 2024, by and between the Registrant and Winston Kung (PMV Pharmaceuticals, Inc., Filed With SEC on February 29, 2024)
Consulting Agreement by and between the Company and Mark McKenna, effective August 1, 2023 (Aeglea BioTherapeutics, Inc., Filed With SEC on February 29, 2024)
Separation and Consulting Agreement and Release of Claims, dated October 4, 2023, by and between Myriad Genetics, Inc. and Nicole Lambert (Myriad Genetics, Inc., Filed With SEC on February 28, 2024)
Separation and Consulting Agreement and Release of Claims, dated December 15, 2023, between Myriad Genetics, Inc. and R. Bryan Riggsbee (Myriad Genetics, Inc., Filed With SEC on February 28, 2024)
Amendment No. 3 to the Consulting Agreement, by and between the Registrant and Dinah Sah, Ph.D., dated May 1, 2023 (Voyager Therapeutics, Inc., Filed With SEC on February 28, 2024)
Amendment No. 2 to the Consulting Agreement, by and between the Registrant and Dinah Sah, Ph.D., dated June 27, 2022 (Voyager Therapeutics, Inc., Filed With SEC on February 28, 2024)
Consulting Agreement, dated February 27, 2024, by and between the Company and Mr. Brian Lenz (ADMA BIOLOGICS, INC., Filed With SEC on February 28, 2024)